Reglan Adverse Events More Than Doubled from 2006 to 2008

... Event Reporting System reveals that new cases of tardive dyskinesia or other movement disorders reported ... their labels about the strong connection between tardive dyskinesia and the long-term use of Reglan. ... Event Reporting System reveals that new cases of tardive dyskinesia or other movement disorders reported ...

Analysis of FDA Adverse Events Data Reveals at Least 106 Serious Conditions Reported Among Reglan Users

... System has identified at least 106 cases of tardive dyskinesia or other movement disorders reported ... Reglan or its generic version, metoclopramide. tardive dyskinesia is a neurological disorder ... System has identified at least 106 cases of tardive dyskinesia or other movement disorders reported ...

New Data Demonstrate RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia

... Treatment should be stopped if the person being treated has NMS. tardive Dyskinesia (TD) is a serious, sometimes permanent side effect reported ... and treatment of any concomitant serious medical problems. tardive Dyskinesia (TD): TD is a syndrome of potentially irreversible, ...

FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder

... Treatment should be stopped if the person being treated has NMS. tardive Dyskinesia (TD) is a serious, sometimes permanent side effect reported ... and treatment of any concomitant serious medical problems. tardive Dyskinesia (TD): TD is a syndrome of potentially irreversible, ...

Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels

... treatment, prescribing should be consistent with the need to minimize tardive Dyskinesia (TD). The risk of developing TD and the likelihood that it will ... treatment, prescribing should be consistent with the need to minimize tardive Dyskinesia (TD). The risk of developing TD and the likelihood that it will ...

FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

... rhythm abnormality, contact your doctor IMMEDIATELY if you feel faint or feel a change in the way that your heart beats (palpitations). tardive Dyskinesia (TD) is a rare, but serious and sometimes permanent side effect reported with INVEGA(R) SUSTENNA(TM) and similar medicines. Call your ...

INVEGA(R) Approved as the First and Only Treatment for Schizoaffective Disorder

... than usual, increased heart rate or blood pressure, or muscle pain or weakness. Treatment should be stopped if you are being treated for NMS. tardive Dyskinesia (TD) is a rare, but serious and sometimes permanent side effect reported with INVEGA(R) and similar medicines. Call your doctor right away ...

Favorable Vote From FDA Advisory Committee on SEROQUEL Pediatric Supplemental New Drug Applications

... neutropenia should be carefully monitored, and SEROQUEL should be discontinued in any patient if the absolute neutrophil count is 1000/mm3. tardive dyskinesia (TD), a potentially irreversible syndrome of involuntary dyskinetic movements, may develop in patients treated with antipsychotic drugs. ...

Olanzapine Long-Acting Injection (LAI) Efficacy and Safety Data Presented at American Psychiatric Association Annual Meeting

... should receive regular monitoring of weight. As with all antipsychotic treatment, prescribing should be consistent with the need to minimize tardive Dyskinesia (TD). The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment ...

FDA Advisory Committee Recommendation on SEROQUEL XR Supplemental New Drug Applications

... be carefully monitored, and SEROQUEL XR and SEROQUEL should be discontinued in any patient if the absolute neutrophil count is < 1000/mm3. tardive dyskinesia (TD), a potentially irreversible syndrome of involuntary dyskinetic movements, may develop in patients treated with antipsychotic drugs. ...

Tardive in Medical Technology

RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder

... Treatment should be stopped if the person being treated has NMS. tardive Dyskinesia (TD) is a serious, sometimes permanent side effect reported ... and treatment of any concomitant serious medical problems. tardive Dyskinesia (TD): TD is a syndrome of potentially irreversible, ...

Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

... rhythm abnormality, contact your doctor IMMEDIATELY if you feel faint or feel a change in the way that your heart beats (palpitations). tardive Dyskinesia (TD) is a rare, but serious and sometimes permanent side effect reported with INVEGA((R)) SUSTENNA(TM) and similar medicines. Call your ...

FDA Advisory Committee Votes in Favor of Zyprexa for Two Adolescent Indications

... should receive regular monitoring of weight. As with all antipsychotic treatment, prescribing should be consistent with the need to minimize tardive Dyskinesia (TD). The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment ...

Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry

... No clinically important differences were observed between lurasidone and placebo for EPS (assessed using the Simpson-Angus Scale) or symptoms of tardive dyskinesia (assessed using the Abnormal Involuntary Movements Scale). There was a modest but significant worsening at endpoint in akathisia symptoms ...

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)

... Some medications interact with paliperidone. Please inform your healthcare professional of any medications or supplements that you are taking. tardive Dyskinesia (TD) is a serious, sometimes permanent side effect reported with paliperidone and similar medications. TD includes uncontrollable ...

FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults

... and acute renal failure. Also, as with all antipsychotic treatment, prescribing should be consistent with the need to minimize tardive Dyskinesia (TD). The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment ...

Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder

... Some medications interact with paliperidone. Please inform your healthcare professional of any medications or supplements that you are taking. tardive Dyskinesia (TD) is a serious, sometimes permanent side effect reported with paliperidone and similar medications. TD includes uncontrollable ...

Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months

... (rhabdomyolysis) and acute renal failure. Also, as with all antipsychotic treatment, prescribing should be consistent with the need to minimize tardive Dyskinesia (TD). The risk of developing TD increases as the duration of treatment. If signs and symptoms of TD are observed a dose reduction or ...

Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference

... (rhabdomyolysis) and acute renal failure. Also, as with all antipsychotic treatment, prescribing should be consistent with the need to minimize tardive Dyskinesia (TD). The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment ...

AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines

... myoglobinuria (rhabdomyolysis), and acute renal failure. The management of NMS should include immediate discontinuation of antipsychotic drugs. tardive dyskinesia (TD), a potentially irreversible syndrome of involuntary dyskinetic movements, may develop in patients treated with antipsychotic drugs. ...

Tardive in Medical Dictionary

Tardive dyskinesia

... tardive dyskinesia Definition: tardive dyskinesia are involuntary movement s, ... a group of medications known as neuroleptics. tardive dyskinesia is a movement disorder that occurs ...

Tardive in Biological Technology

Neurocrine Biosciences Reports Second Quarter 2009 Results

... NBI-98854 should be of clinical benefit in patients with a variety of CNS diseases, especially those with involuntary hyperkinetic movements such as tardive Dyskinesia. A Clinical Trial Application has been approved by Health Canada and we will initiate a single ascending dose Phase 1 study in August ....

Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting

... WARNINGS and PRECAUTIONS: increased mortality in elderly patients with dementia-related psychosis; QT prolongation; neuroleptic malignant syndrome; tardive dyskinesia; hyperglycemia and diabetes mellitus; weight gain; seizures; orthostatic hypotension and syncope; leukopenia, neutropenia and ...

Neurocrine Biosciences Reports First Quarter 2009 Results

... be effective in the management of hyperkinetic movement disorders characterized by involuntary bodily movements as seen in patients suffering from tardive dyskinesia, and Huntington's disease. Additionally, the modulation of dopamine pathways may also be useful for patients suffering from ....

FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder

... changes in pulse, heart rate, or blood pressure; or muscle pain and weakness. Treatment should be stopped if the person being treated has NMS. tardive Dyskinesia (TD) is a serious, sometimes permanent side effect reported with RISPERDAL(R) CONSTA(R) and similar medications. TD includes ...

Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia

... medications interact with paliperidone. Please inform your healthcare professional of any medications or supplements that you are taking. tardive Dyskinesia (TD) is a serious, sometimes permanent side effect reported with paliperidone and similar medications. TD includes uncontrollable ...

Lilly to Take Charge to Earnings Related to Pending Federal and State Investigations of Past Practices

... (rhabdomyolysis), and acute renal failure. Also, as with all antipsychotic treatments, prescribing should be consistent with the need to minimize tardive Dyskinesia (TD). The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment ...

FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania

... should be carefully monitored, and SEROQUEL XR should be discontinued in any patient if the absolute neutrophil count is < 1000/mm.(3) tardive dyskinesia (TD), a potentially irreversible syndrome of involuntary dyskinetic movements, may develop in patients treated with antipsychotic drugs. ...

Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources

... Some medications interact with paliperidone. Please inform your healthcare professional of any medications or supplements that you are taking. tardive Dyskinesia (TD) is a serious, sometimes permanent side effect reported with paliperidone and similar medications. TD includes uncontrollable ...

AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder

... myoglobinuria (rhabdomyolysis), and acute renal failure. The management of NMS should include immediate discontinuation of antipsychotic drugs. tardive dyskinesia (TD), a potentially irreversible syndrome of involuntary dyskinetic movements, may develop in patients treated with antipsychotic drugs. ...

U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)

... pulse or blood pressure, cardiac dysrhythmia, and altered mental status. If signs and symptoms appear, immediate discontinuation is recommended tardive dyskinesia (TD)-The risk of developing TD and the potential for it to become irreversible may increase as the duration of treatment and the total ...